Deleterious mutations (e. g., protein-deleting or -truncating) in DNA MMR genes unambiguously allow for the clinical diagnosis LS and hence enable appropriate surveillance measures to be taken to reduce cancer risk and ensure early detection of tumors. This evidence concerns the gene MRC1 and Leigh syndrome.